Pravastatin and Cyclosporine Interaction

Understanding the Pravastatin and Cyclosporine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Pravastatin belongs to the HMG-CoA Reductase Inhibitor (Statin) class and Cyclosporine belongs to the Calcineurin Inhibitor (Immunosuppressant) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Cyclosporine causes more of the statin to stay in your blood, which can lead to muscle damage. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Pravastatin has 16 total documented interactions on file in this dataset, and Cyclosporine has 89. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to change your dose or watch you closely for signs of muscle weakness. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Pravastatin or Cyclosporine based on a web page, speak with your prescriber or pharmacist before making any change.